Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-4719
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Combination Therapy for Treating Breast Cancer Using Antiestrogen, ERA-923, and the Mammalian Target of Rapamycin Inhibitor, Temsirolimus

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2006English

Correction: An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-Resistant Functions of mTORC1.

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2020English

Ku-0063794 Is a Specific Inhibitor of the Mammalian Target of Rapamycin (mTOR)

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2009English

Mammalian Target of Rapamycin (mTOR; FRAP; RAFT1)

Science-Business eXchange
2010English

Mammalian Target of Rapamycin: A Target for (Lung) Diseases and Aging

Annals of the American Thoracic Society
PulmonaryRespiratory Medicine
2016English

Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases

Biomedical Journal
Medicine
2013English

The Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Early Breast Cancer: Results of a Pre-Operative Study

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Emerging Role for Mammalian Target of Rapamycin in Male Fertility

Trends in Endocrinology and Metabolism
EndocrinologyMetabolismDiabetes
2017English

Mammalian Target of Rapamycin Signaling in Cardiac Physiology and Disease

Circulation Research
Cardiovascular MedicinePhysiologyCardiology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy